Publications by authors named "Derek D Best"

Claim this Profile
L
Legacy hERG study data in contemporary integrated risk assessments - mitigating the risk of protocol and positive control article differences.
Richard W Daniels, James W Kramer, Matthew M Abernathy, Derek D Best, Jessica C Brimecombe

J Pharmacol Toxicol Methods· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telemetry in toxicology studies - A comparison of data across species, technologies and time.
Derek D Best, Matthew M Abernathy, Derek J Leishman

J Pharmacol Toxicol Methods· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The statistical and pharmacological sensitivity of nonclinical QTc analysis comparing jacketed telemetry and multilead snapshot recording in the same dogs.
Matthew M Abernathy, Derek D Best, Derek J Leishman

J Pharmacol Toxicol Methods· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstrating the statistical and pharmacological sensitivity of nonclinical QTc analysis using a dofetilide dose-response in nonhuman primates.
Derek J Leishman, David L Holdsworth, Derek D Best, Matthew M Abernathy, Brian M Roche

J Pharmacol Toxicol Methods· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation.
Matthew M Abernathy, Derek D Best, Derek J Leishman

Clin Pharmacol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A "one-step" approach to heart rate correction and statistical analysis applied to conscious dog QTc studies.
Derek D Best, Matthew M Abernathy, Derek J Leishman

Clin Transl Sci· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the performance of contemporary, historical, and cross-lab controls in QTc assessment in conscious nonhuman primates.
Matthew M Abernathy, Derek D Best, Derek J Leishman

J Pharmacol Toxicol Methods· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the sensitivity of cross-over and parallel study designs for QTc assessment: An analysis based on a single large study of moxifloxacin in 48 nonhuman primates.
Derek J Leishman, David L Holdsworth, Derek D Best, Brian M Roche

J Pharmacol Toxicol Methods· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of validity of standard nonclinical group size selection versus standard clinical group sizes for nonhuman primate QTc prolongation evaluation.
David Holdsworth, Derek D Best, Katarina Haist, Kyle O'Donohue, Anson Phillips

J Pharmacol Toxicol Methods· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
Vincent L Reynolds, Paul Butler, Matthew M Abernathy, Laura Aschenbrenner, Derek D Best

Regul Toxicol Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis